Searchable abstracts of presentations at key conferences in endocrinology

ea00100wg2.1 | Workshop G: Disorders of appetite and weight | SFEEU2024

Continuous glucose monitoring in the management of post-bariatric hypoglycaemia – does it have a place in treatment algorithms utilised by the NHS?

Sarkar Priscilla , Hamza Malak , Ahmad Ehtasham , Papamargaritis Dimitris

Post-bariatric-surgery hypoglycaemia (PBH) typically presents at least six months post-operatively, particularly in those who have undergone Roux-en-Y gastric bypass (RYGB), with the literature suggesting that this condition develops in up to 30% of people post-bypass surgery. PBH is characterised by high postprandial insulin and glucagon-like peptide-1 secretion leading to hypoglycaemia 1-3 hours after consumption of meals that are high in carbohydrate content. We present the...

ea0062cb3 | Additional Cases | EU2019

Endocrinopathies post immune check point inhibitors

Hamza Malak , Van Heeswijk Isabelle , Yahia Seif , Fernando Devaka , Abdulla Haitham , Muraleedharan Vakkat

Introduction: Immune adverse related events are commonly recognized complications of immune check point inhibitors. Here we identify multiple endocrinopathies occurring concurrently in the same patient. In addition to highlighting the common immune adverse effects seen in other cases.Case 1: 33F Refractory Hodgkins Lymphoma tried on several therapies. She was started on Nivolumab (PD-1) with remarkable response. She developed symptoms of Amenorrhea, gala...

ea0063p340 | Thyroid 1 | ECE2019

Endocrinopathies post Immune check point inhibitors

Hamza Malak , Van Heeswijk Isabelle , Yahia Seif , Fernando Devaka , Abdulla Haitham , Muraleedharan Vakkat

Introduction: Immune adverse related events are commonly recognized complications of immune check point inhibitors. Here we identify multiple endocrinopathies occurring concurrently in the same patient. In addition to highlighting the common immune adverse effects seen in other cases.Case 1: 33F Refractory Hodgkins Lymphoma tried on several therapies. She was started on Nivolumab (PD-1) with remarkable response. She developed symptoms of Amenorrhea, gala...

ea0081p253 | Late-Breaking | ECE2022

Central diabetes insipidus from a patients′ perspective – from management to psychological co-morbidities and re-naming of the condition

Atila Cihan , Loughrey Ben , Garrahy Aoife , Winzeler Bettina , Refardt Julie , Gildroy Patricia , Pal Aparna , Hamza Malak , Thompson Chris , Verbalis Joseph , Hunter Steven , Sherlock Mark , J Levy Miles , Karavitaki Niki , Newell-Price John , Wass John , Christ-Crain Mirjam

Background: Central diabetes insipidus (cDI), a rare neuroendocrine condition affecting 1 in 25.000, is characterized by deficiency of arginine vasopressin. Data about treatment-related side effects, psychological co-morbidities, and incidence of wrong management due to confusion with diabetes mellitus are scarce and limited to small studies or case series. Furthermore, increasing interest has arisen on a potential need for re-naming the condition.<p class="abstex...